The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
PET of Somatostatin Receptor–Positive Tumors Using 64Cu- and 68Ga-Somatostatin Antagonists: The Chelate Makes the Difference
Abstract
UNLABELLED: Somatostatin-based radiolabeled peptides have been successfully introduced into the clinic for targeted imaging and radionuclide therapy of somatostatin receptor (sst)-positive tumors, especially of subtype 2 (sst2). The clinically used peptides are exclusively agonists. Recently, we showed that radiolabeled antagonists may be preferable to agonists because they showed better pharmacokinetics, including higher tumor uptake. Factors determining the performance of radioantagonists have only scarcely been studied. Here, we report on the development and evaluation of four (64)Cu or (68)Ga radioantagonists for PET of sst2-positive tumors. METHODS: The novel antagonist p-Cl-Phe-cyclo(D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr-NH(2) (LM3) was coupled to 3 macrocyclic chelators, namely 4,11-bis(carboxymethyl)-1,4,8,11-tetraazabicyclo[6.6.2]hexadecane (CB-TE2A), 1,4,7-triazacyclononane,1-glutaric acid-4,7-acetic acid (NODAGA), and DOTA. (64/nat)Cu- and (68/nat)Ga-NODAGA-LM3 were prepared at room temperature, and (64/nat)Cu-CB-TE2A-LM3 and (68/nat)Ga-DOTA-LM3 were prepared at 95°C. Binding affinity and antagonistic properties were determined with receptor autoradiography and immunofluorescence microscopy using human embryonic kidney (HEK)-sst2 cells. In vitro internalization and dissociation was evaluated using the same cell line. Biodistribution and small-animal PET studies were performed with HEK-sst2 xenografts. RESULTS: All metallopeptides demonstrated antagonistic properties. The affinities depend on chelator and radiometal and vary about 10-fold; (68/nat)Ga-NODAGA-LM3 has the lowest half maximal inhibitory concentration (1.3 ± 0.3 nmol/L). The biodistribution studies show impressive tumor uptake at 1 h after injection, particularly of (64)Cu- and (68)Ga-NODAGA-LM3 (∼40 percentage injected dose per gram of tissue [%ID/g]), which were proven to be specific. Background clearance was fast and the tumor washout relatively slow for (64)Cu-NODAGA-LM3 (∼15 %ID/g, 24 h after injection) and almost negligible for (64)Cu-CB-TE2A-LM3 (26.9 ± 3.3 %ID/g and 21.6 ± 2.1 %ID/g, 4 and 24 h after injection, respectively). Tumor-to-normal-tissue ratios were significantly higher for (64)Cu-NODAGA-LM3 than for (64)Cu-CB-TE2A-LM3 (tumor-to-kidney, 12.8 ± 3.6 and 1.7 ± 0.3, respectively; tumor-to-muscle, 1,342 ± 115 and 75.2 ± 8.5, respectively, at 24 h, P < 0.001). Small-animal PET shows clear tumor localization and high image contrast, especially for (64)Cu- and (68)Ga-NODAGA-LM3. CONCLUSION: This article demonstrates the strong dependence of the affinity and pharmacokinetics of the somatostatin-based radioantagonists on the chelator and radiometal. (64)Cu- and (68)Ga-NODAGA-LM3 and (64)Cu-CB-TE2A-LM3 are promising candidates for clinical translation because of their favorable pharmacokinetics and the high image contrast on PET scans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kwekkeboom, D. J., de Herder, W. W., Kam, B. L., van Eijck, C. H., van Essen, M., Kooij, P. P., Feelders, R. A., van Aken, M. O., & Krenning, E. P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.2553 · Cited by 1,456
Reubi, J. C., Schär, J.-C., Waser, B., Wenger, S., Heppeler, A., Schmitt, J. S., & Mäcke, H. R. (2000) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590050034 · Cited by 1,127 · cited 2×
“The half maximal inhibitory concentration (IC50) was estimated for each metallopeptide by complete displacement experiments using the universal somatostatin radioligand [Leu8,D-Trp22,125 I-Tyr25]-somatostatin-28 (Anawa) and increasing concentrations of the metallopeptide, as previously described (21,22).”
MethodSelf-citationAMIDE: A Free Software Tool for Multimodality Medical Image Analysis
Loening, A. M., & Gambhir, S. S. (2003) · Molecular Imaging · doi:10.1162/15353500200303133 · Cited by 1,018
Reubi, J., Waser, B., Schaer, J.-C., & Laissue, J. A. (2001) · European Journal of Nuclear Medicine · doi:10.1007/s002590100541 · Cited by 657
Self-citationKenakin, T., & Miller, L. J. (2010) · Pharmacological Reviews · doi:10.1124/pr.108.000992 · Cited by 573
Ginj, M., Zhang, H., Waser, B., Cescato, R., Wild, D., Wang, X., Erchegyi, J., Rivier, J., Mäcke, H. R., & Reubi, J. C. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607761103 · Cited by 515
Self-citationSomatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors
Kwekkeboom, D. J., Kam, B. L., van Essen, M., Teunissen, J. J. M., van Eijck, C. H. J., Valkema, R., de Jong, M., de Herder, W. W., & Krenning, E. P. (2010) · Endocrine-Related Cancer · doi:10.1677/erc-09-0078 · Cited by 466
Antunes, P., Ginj, M., Zhang, H., Waser, B., Baum, R. P., Reubi, J. C., & Maecke, H. (2007) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-006-0317-x · Cited by 393
Self-citationSrirajaskanthan, R., Kayani, I., Quigley, A. M., Soh, J., Caplin, M. E., & Bomanji, J. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.066134 · Cited by 310
90Y-Edotreotide for Metastatic Carcinoid Refractory to Octreotide
Bushnell, D. L., O'Dorisio, T. M., O'Dorisio, M. S., Menda, Y., Hicks, R. J., Van Cutsem, E., Baulieu, J.-L., Borson-Chazot, F., Anthony, L., Benson, A. B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.8585 · Cited by 306
Long‐lasting target binding and rebinding as mechanisms to prolong in vivo drug action
Vauquelin, G., & Charlton, S. J. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00936.x · Cited by 298
Copper Chelation Chemistry and its Role in Copper Radiopharmaceuticals
Wadas, T., Wong, E., Weisman, G., & Anderson, C. (2007) · Current Pharmaceutical Design · doi:10.2174/138161207779313768 · Cited by 296
68Ga-DOTANOC PET/CT Clinical Impact in Patients with Neuroendocrine Tumors
Ambrosini, V., Campana, D., Bodei, L., Nanni, C., Castellucci, P., Allegri, V., Montini, G. C., Tomassetti, P., Paganelli, G., & Fanti, S. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.071712 · Cited by 232
Eisenwiener, K.-P., Prata, M. I. M., Buschmann, I., Zhang, H.-W., Santos, A. C., Wenger, S., Reubi, J. C., & Mäcke, H. R. (2002) · Bioconjugate Chemistry · doi:10.1021/bc010074f · Cited by 213
Self-citationPrasanphanich, A. F., Nanda, P. K., Rold, T. L., Ma, L., Lewis, M. R., Garrison, J. C., Hoffman, T. J., Sieckman, G. L., Figueroa, S. D., & Smith, C. J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705347104 · Cited by 213
Gabriel, M., Oberauer, A., Dobrozemsky, G., Decristoforo, C., Putzer, D., Kendler, D., Uprimny, C., Kovacs, P., Bale, R., & Virgolini, I. J. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.053421 · Cited by 188
Roesch, F., & J. Riss, P. (2010) · Current Topics in Medicinal Chemistry · doi:10.2174/156802610793176738 · Cited by 187
Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists.
Cescato, R., Schulz, S., Waser, B., Eltschinger, V., Rivier, J., Wester, H.-J., Culler, M. D., Ginj, M., Liu, Q., Schönbrunn, A., et al. (2006) · PubMed · Cited by 183
Self-citationCescato, R., Érchegyi, J., Waser, B., Piccand, V., Maëcke, H. R., Rivier, J., & Reubi, J. C. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701618q · Cited by 116
Self-citationWaser, B., Tamma, M., Cescato, R., Maëcke, H. R., & Reubi, J. C. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.061457 · Cited by 112
Self-citationJiang, G., Stalewski, J., Galyean, R., Dykert, J., Schteingart, C. D., Broqua, P., Aebi, A., Aubert, M. L., Semple, G., Robson, P. A., et al. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm0003900 · Cited by 109
Wadas, T. J., Eiblmaier, M., Zheleznyak, A., Sherman, C. D., Ferdani, R., Liang, K., Achilefu, S., & Anderson, C. J. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.054502 · Cited by 73
Ginj, M., Zhang, H., Eisenwiener, K., Wild, D., Schulz, S., Rink, H., Cescato, R., Reubi, J. C., & Maëcke, H. R. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1687 · Cited by 73
Self-citationDeshmukh, M. V., Voll, G., Kühlewein, A., Mäcke, H. R., Schmitt, J. S., Kessler, H., & Gemmecker, G. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0496335 · Cited by 45
Fani, M., Mueller, A., Tamma, M., Nicolas, G., Rink, H. R., Cescato, R., Reubi, J. C., & Maëcke, H. R. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.076695 · Cited by 39
Self-citation
Cited by
Matching chelators to radiometals for radiopharmaceuticals
Price, E. W., & Orvig, C. (2014) · Chem. Soc. Rev. · doi:10.1039/c3cs60304k · Cited by 1,018
Somatostatin receptors: From signaling to clinical practice
Theodoropoulou, M., & Stalla, G. K. (2013) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2013.07.005 · Cited by 410
Prospective of 68Ga-Radiopharmaceutical Development
Velikyan, I. (2014) · Theranostics · doi:10.7150/thno.7447 · Cited by 336
Radiolabeled Peptides: Valuable Tools for the Detection and Treatment of Cancer
Fani, M., Maecke, H. R., & Okarvi, S. M. (2012) · Theranostics · doi:10.7150/thno.4024 · Cited by 333
Self-citationSomatostatin receptor antagonists for imaging and therapy.
Fani, M., Nicolas, G. P., & Wild, D. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.186783 · Cited by 274
“On the basis of the new sstr2 antagonist LM3 (p-Cl-Phe-cyclo (D-Cys-Tyr-D-Aph(Cbm)-Lys-Thr-Cys)D-Tyr-NH2), various PET imaging agents were developed using 3 different macrocyclic chelating systems (DOTA, NODAGA, and CB-TE2A) and 2 PET radiometals (68Ga and 64Cu) (16).”
BackgroundMethod
Metadata
- Authors
- Fani, M., Del Pozzo, L., Abiraj, K., Mansi, R., Tamma, M. L., Cescato, R., Waser, B., Weber, W. A., Reubi, J. C., & Maecke, H. R.
- Venue
- Journal of Nuclear Medicine
- Publisher
- Society of Nuclear Medicine
- Published
- 2011-06-16
- Volume
- 52
- Issue
- 7
- Pages
- 1110-1118
- ISSN
- 0161-5505 (ISSN-L)
- 2159-662X
- OpenAlex
- W2049089156
- Cited by
- 262
- References
- 25
- FWCI
- 14.71
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.